U.S. Markets closed

QIAGEN Launches FFPE and Liquid Biopsy PIK3CA Diagnostics in Europe to Enhance Precision Medicine in Advanced Breast Cancer

  • Innovative therascreen® PIK3CA RGQ PCR Kit CE-marked for use in guiding treatment decisions for breast cancer patients
  • Test detects activating mutations in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene
  • CE-IVD approved therascreen assay will be available to labs in Europe starting immediately

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the CE-marking and launch of its therascreen® PIK3CA RGQ PCR Kit in Europe as an aid in identifying breast cancer patients with a PIK3CA mutation. Last year the therascreen PIK3CA test was approved by the FDA and launched as a companion diagnostic test for Piqray® (alpelisib) in the US.

The therascreen PIK3CA test is a new diagnostic assay for detection of activating mutations in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene, and the first to enable testing of both DNA from FFPE tissue or plasma specimens. All QIAGEN therascreen PIK3CA tests leverage QIAGEN’s worldwide co-exclusive license from Johns Hopkins University for PCR-based companion diagnostics based on detection of mutations in the PIK3CA gene.

1 in 8 women in Europe will develop breast cancer before the age of 85, making it the most common form of cancer in female patients. The therascreen assay detects 11 clinically actionable PIK3CA mutations, which are estimated to be present in approximately 40% of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+ HER2-) advanced breast cancer cases.

"This launch in Europe further underscores our commitment to support patients with breast cancer, the most common cancer in female cancer patients, with an estimated incidence of 562,500 in Europe in 2018 according to the WHO" said Jonathan Arnold, Vice President, Head of Oncology and Precision Diagnostics. "We are convinced that our therascreen PIK3CA Kit, which expands our market-leading therascreen portfolio of companion diagnostics, will provide a valuable testing option for those seeking new ways to combat advanced breast cancer. We are committed to making the therascreen PIK3CA Kit available immediately so that leading laboratories in Europe can provide patients with the test as soon as possible."

Please find the full press release here

Additional information can be found at www.qiagen.com/cmp/mdx/pik3ca-rgq-pcr-kit-row/

View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005744/en/


Investor Relations
John Gilardi
+49 2103 29 11711
Phoebe Loh
+49 2103 29 11457
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer
+49 2103 29 11826
Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com